Everest Medicines' LEROCHOL® Nears Chinese Approval with NMPA BLA Acceptance
Event summary
- China's NMPA accepted Everest Medicines' Biologics License Application for LEROCHOL®, a third-generation PCSK9 inhibitor, targeting hypercholesterolemia.
- Phase 3 trials in China showed mean LDL-C reductions of 65.9% at week 12 and 67.0% at weeks 10-12, with over 95% of participants meeting Chinese guideline targets.
- LEROCHOL® is already FDA-approved (since December 2025) and under EMA review, positioning it as a potential best-in-class treatment for cardiovascular disease.
- The drug offers unique advantages including monthly subcutaneous dosing and up to 3-month room temperature stability.
The big picture
Everest Medicines' progress with LEROCHOL® underscores the growing focus on innovative cardiovascular treatments in China, where cardiovascular disease remains the leading cause of death. The NMPA's acceptance of the BLA positions Everest to capitalize on a significant unmet medical need, particularly among patients with familial hypercholesterolemia who struggle to meet LDL-C targets with existing therapies.
What we're watching
- Regulatory Timing
- Whether Everest Medicines can secure NMPA approval by late 2027, enabling commercialization in Greater China.
- Market Penetration
- How the company will address the low treatment penetration (14%) among China's 400 million dyslipidemia patients.
- Competitive Positioning
- The pace at which LEROCHOL® can differentiate itself against existing lipid-lowering therapies in a crowded market.
Related topics